Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Incorporated

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioMarin Pharmaceutical (BMRN), Zoetis (ZTS) and Vertex Pharmaceu...

Analysts Conflicted on These Healthcare Names: BioMarin Pharmaceutical (BMRN), Zoetis (ZTS) and Vertex Pharmaceuticals (VRTX)

WSW, NY, July 23rd, 2026, FinanceWire Nuvectis Pharma (NASDAQ:NVCT) announced this morning that ciprocopan (NXP100) has been approved by China’s Na...

Nuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor

Vertex Pharmaceuticals Inc. ($VRTX) announced an update on their ongoing clinical study. Vertex Pharmaceuticals Inc. is running a Phase 1 study cal...

Vertex’s VX-581 Dose Escalation Trial: A Fresh Signal on Cystic Fibrosis Pipeline Strength

BMO Capital analyst Evan Seigerman maintained a Buy rating on Vertex Pharmaceuticals today and set a price target of $600.00. Seigerman covers the ...

BMO Capital Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Certara (CERT), Nurix Therapeutics (NRIX) and Vertex Pharmaceutic...

Analysts Conflicted on These Healthcare Names: Certara (CERT), Nurix Therapeutics (NRIX) and Vertex Pharmaceuticals (VRTX)

Barclays analyst Eliana Merle maintained a Buy rating on Vertex Pharmaceuticals today and set a price target of $615.00. According to TipRanks, Mer...

Vertex Pharmaceuticals (VRTX) Receives a Buy from Barclays

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (VRTX) and Kuros Biosciences ...

Analysts Are Bullish on Top Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Kuros Biosciences (CSBTF)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Insmed (INSM), Biogen (BIIB) and Vertex Pharmaceutic...

Analysts Are Bullish on These Healthcare Stocks: Insmed (INSM), Biogen (BIIB)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aligos Therapeutics (ALGS) and Vertex Pharmaceutical...

Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (ALGS) and Vertex Pharmaceuticals (VRTX)

TD Cowen analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals today and set a price target of $525.00. Nadeau covers the Healthcar...

TD Cowen Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)

Scotiabank analyst Louise Chen maintained a Buy rating on Vertex Pharmaceuticals today and set a price target of $558.00. Chen covers the Healthcar...

Scotiabank Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)

Crinetics Pharmaceuticals ($CRNX) stock surged nearly 100% in pre-market trading on Tuesday after Vertex Pharmaceuticals ($VRTX) agreed to acquire ...

Why Is Crinetics Stock (CRNX) Surging Nearly 100% in Pre-Market Today, 7/7/26? Analysts React

Vertex Pharmaceuticals ($VRTX) fell about 2.3% after hours on Monday following a deal to acquire endocrine‑focused drugmaker Crinetics Pharmaceutic...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VRTX	$490.39	+2.38%	1.70M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VRTX	$490.39	+2.4%	1.70M
3
4
5
6

VRTX

VRTX

Get Vertex Pharmaceuticals Incorporated Data in Excel

Get Vertex Pharmaceuticals Incorporated Data in Excel